IMPACT (INOVIO INO-4802 Multi-variant Pan- COVID-19 Vaccine Trial)
• In parallel with INO-4800, INOVIO is developing a second generation, pan-COVID vaccine candidate, INO-4802
• Strategy against current and future variants of concern
• Can potentially provide boosting capabilities in addition to an initial vaccination regimen with INO-4800 and/or other first-generation vaccines, including both adenovirus and mRNA-based platforms
*Manuscript published as a preprint in bioRxiv, “Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine”; Posted August 04, 2021
• Cross-reactive immune responses demonstrated against current and emerging viral variants*
• Induced potent neutralizing antibodies, T cell responses, and protection in a pre-clinical model against the original wildtype strain as well as against the alpha, beta, gamma, and delta variants
Applied for CEPI, BARDA, NIAID fundings
Platform Development
? 3Q21: Initiate Phase 2 MERS study with INO-4700 funded by CEPI
? 4Q21: Fully enroll Phase 1B field study for Lassa with INO-4500 funded by CEPI
? 4Q21: Fully enroll Phase 1 Ebola study with INO-4201 as a booster to Ervebo®
INO-4800
? 1H22: Report interim efficacy data from Phase 3 INNOVATE trial
VGX-3100
? 4Q21: Report complete REVEAL 1 data (ITT, mITT, per protocol)
? 4Q21: Report on pre-treatment biomarker with QIAGEN
INO-5401
? 4Q20: OS18 data from Phase 1/2 GBM clinical trial (INO-5401 plus Libtayo®)
? 4Q21: Present 24-month overall survival and immunology data
HPV-associated disease; caused by HPV 6 and 11
• Rare, orphan disease with ~15,000 total active cases within the U.S., where virtually all of those require surgical procedures
• ~6,000 new cases per yr. in the U.S.
• Growths can lead to life-threatening airway obstructions
• SoC is lifelong surgery (repeated/multiple times per yr)
• Currently, disease is incurable and can only be treated by surgery to remove tumors, which temporarily restores the airway
• RRP may occur in adults as well as in children who are thought to have contracted the virus during childbirth
• INO-3107 granted Orphan Drug Designation in July 2020
• Dosed first patient in Ph 1/2 trial in November 2020 (n=63)
